66,365 Shares in Biogen Inc. $BIIB Bought by Danske Bank A S

Danske Bank A S bought a new stake in Biogen Inc. (NASDAQ:BIIB) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 66,365 shares of the biotechnology company’s stock, valued at approximately $14,339,000.

Several other institutional investors also recently made changes to their positions in BIIB. Rothschild Investment LLC lifted its stake in shares of Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares during the period. Meeder Advisory Services Inc. grew its position in Biogen by 1.2% during the first quarter. Meeder Advisory Services Inc. now owns 4,721 shares of the biotechnology company’s stock worth $866,000 after buying an additional 57 shares during the period. Kera Capital Partners Inc. increased its holdings in Biogen by 3.5% in the first quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after buying an additional 58 shares in the last quarter. Parallel Advisors LLC increased its holdings in Biogen by 1.5% in the first quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock valued at $801,000 after buying an additional 65 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its position in shares of Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 66 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

BIIB has been the topic of several recent research reports. Canaccord Genuity Group boosted their price objective on shares of Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Barclays upped their price target on shares of Biogen from $185.00 to $200.00 and gave the company an “equal weight” rating in a report on Wednesday, July 29th. Mizuho raised their price objective on shares of Biogen from $221.00 to $241.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Sanford C. Bernstein cut their price objective on Biogen from $201.00 to $200.00 in a research report on Thursday, April 30th. Finally, Truist Financial raised Biogen from a “hold” rating to a “buy” rating and upped their target price for the company from $190.00 to $235.00 in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Biogen has an average rating of “Moderate Buy” and a consensus target price of $227.07.

Biogen Price Performance

NASDAQ:BIIB opened at $214.35 on Friday. The firm has a market cap of $31.67 billion, a price-to-earnings ratio of 37.94, a price-to-earnings-growth ratio of 6.90 and a beta of 0.17. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39. The company’s 50-day moving average is $205.20 and its two-hundred day moving average is $194.32. Biogen Inc. has a 12-month low of $131.52 and a 12-month high of $222.15.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 EPS for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. Research analysts expect that Biogen Inc. will post 12.39 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.